剂量递增调强放疗同步放化疗对晚期胸段食管鳞癌有效
本研究基于台湾癌症登记数据库分析2061例无远处转移的胸段食管鳞癌患者,比较IMRT同步放化疗剂量<60Gy与≥60Gy的疗效。多因素分析显示≥60Gy是总生存的独立预后因素(aHR 0.75,95%CI 0.63-0.83,P<0.0001)。在晚期(IIIA-IIIC)患者中,高剂量组总死亡风险显著降低(aHR 0.75,95%CI 0.67-0.83,P<0.0001),而早期患者无显著获益。
要点
- 高剂量IMRT同步放化疗(≥60Gy)与晚期胸段食管鳞癌总生存改善独立相关。
- 晚期(IIIA-IIIC)患者高剂量组总死亡风险显著降低(aHR 0.75,P<0.0001)。
- 早期(IA-IIB)患者高剂量组总死亡风险无显著差异(aHR 0.89,P=0.1905)。
核心结论
- 与标准剂量IMRT同步放化疗相比,高剂量IMRT同步放化疗在晚期胸段食管鳞癌患者中带来更有利的生存结局。
研究设计与样本
- 基于台湾癌症登记数据库的回顾性队列研究,纳入2061例无远处转移的胸段食管鳞癌患者。
- 按放疗剂量分为两组:组1接受IMRT同步放化疗<60Gy,组2接受≥60Gy,以组1为对照分析治疗后死亡风险。
主要发现
- 多因素Cox回归显示晚期AJCC分期(≥IIIA)、饮酒和吸烟是IMRT同步放化疗患者显著的独立不良预后因素。
- IMRT同步放化疗剂量≥60Gy是总生存的显著独立预后因素(aHR 0.75,95%CI 0.63-0.83,P<0.0001)。
- 调整混杂因素后,组2所有临床分期的总死亡aHR为0.75(95%CI 0.68-0.83,P<0.0001)。
- 组2中早期(IA-IIB)和晚期(IIIA-IIIC)AJCC临床分期的总死亡aHR分别为0.89(95%CI 0.70-1.04,P=0.1905)和0.75(95%CI 0.67-0.83,P<0.0001)。
临床怎么用
- 对于晚期(IIIA-IIIC)胸段食管鳞癌患者,可考虑采用IMRT同步放化疗剂量≥60Gy以改善生存。
- 早期(IA-IIB)患者采用≥60Gy未见显著生存获益,决策时需权衡剂量递增的获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: No studies have investigated the effects of irradiation-dose escalation intensity-modulated radiotherapy (IMRT)-based concurrent chemoradiotherapy (CCRT) in patients with thoracic esophageal squamous cell carcinoma (TESCC). PATIENTS AND METHODS: We analyzed data from patients with TESCC who were enrolled in the Taiwan Cancer Registry database. To compare treatment outcomes, the patients were categorized into two groups according to their radiotherapy doses: group 1, who received CCRT<60Gy with IMRT, and group 2, who received CCRT≥60Gy with IMRT. Group 1 was used as the control for investigating posttreatment mortality risk. RESULTS: We enrolled 2061 patients with TESCC without distant metastasis who received CCRT with IMRT. Multivariate Cox regression analysis indicated that advanced clinical American Joint Committee on Cancer (AJCC) stage (≥IIIA), alcohol consumption, and cigarette smoking were significant, poor independent predictors in patients with TESCC receiving IMRT-based CCRT. IMRT-based CCRT (≥60Gy; adjusted hazard ratio [aHR]: 0.75; 95% confidence interval [CI]: 0.63-0.83) was a significant independent prognostic factor for overall survival (P<0.0001). After adjustment for confounders, the aHRs (95% CIs) for overall mortality at all clinical stages were 0.75 (0.68-0.83, P<0.0001) in group 2. In group 2, the aHRs (95% CIs) for overall mortality at early (IA-IIB) and advanced (IIIA-IIIC) AJCC clinical stages were 0.89 (0.70-1.04, P=0.1905) and 0.75 (0.67-0.83, P<0.0001), respectively. CONCLUSION: Compared with standard-dose IMRT-based CCRT, high-dose IMRT-based CCRT yields more favorable survival outcomes in patients with advanced-stage TESCC.
引用
- Chang CL, Tsai HC, Lin WC, et al. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma. Radiother Oncol. 2017. PMID: 28923576. doi:10.1016/j.radonc.2017.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。